{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:12:17Z","timestamp":1790820737122,"version":"4.1.0"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T00:00:00Z","timestamp":1677974400000},"content-version":"am","delay-in-days":308,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001819","name":"International Rett Syndrome Foundation","doi-asserted-by":"publisher","award":["3503"],"award-info":[{"award-number":["3503"]}],"id":[{"id":"10.13039\/100001819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["F31MH119699"],"award-info":[{"award-number":["F31MH119699"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 GM007628"],"award-info":[{"award-number":["T32 GM007628"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K01MH112983"],"award-info":[{"award-number":["K01MH112983"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS112171"],"award-info":[{"award-number":["R01NS112171"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.neuropharm.2022.109022","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T19:01:31Z","timestamp":1646334091000},"page":"109022","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Exploration of group II metabotropic glutamate receptor modulation in mouse models of Rett syndrome and MECP2 Duplication syndrome"],"prefix":"10.1016","volume":"209","author":[{"given":"Sheryl Anne D.","family":"Vermudez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3593-7632","authenticated-orcid":false,"given":"Aditi","family":"Buch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco G.","family":"Gogliotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen M.","family":"Niswender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2022.109022_bib1","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1523\/JNEUROSCI.4225-08.2009","article-title":"MeCP2-mediated transcription repression in the basolateral amygdala may underlie heightened anxiety in a mouse model of Rett syndrome","volume":"29","author":"Adachi","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109022_bib2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/13810","article-title":"Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2","volume":"23","author":"Amir","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2022.109022_bib3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.nbd.2005.07.005","article-title":"Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome","volume":"21","author":"Asaka","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2022.109022_bib4","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0134-19.2019","article-title":"Mecp2 deletion from cholinergic neurons selectively impairs recognition memory and disrupts cholinergic modulation of the perirhinal cortex","volume":"6","author":"Ballinger","year":"2019","journal-title":"eNeuro"},{"key":"10.1016\/j.neuropharm.2022.109022_bib5","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1093\/cercor\/bhv078","article-title":"Defects during mecp2 null embryonic cortex development precede the onset of overt neurological symptoms","volume":"26","author":"Bedogni","year":"2016","journal-title":"Cerebr. Cortex"},{"key":"10.1016\/j.neuropharm.2022.109022_bib6","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1093\/hmg\/ddp181","article-title":"Mouse models of MeCP2 disorders share gene expression changes in the cerebellum and hypothalamus","volume":"18","author":"Ben-Shachar","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2022.109022_bib7","doi-asserted-by":"crossref","first-page":"19796","DOI":"10.1038\/srep19796","article-title":"Pharmacological treatment with mirtazapine rescues cortical atrophy and respiratory deficits in MeCP2 null mice","volume":"6","author":"Bittolo","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2022.109022_bib8","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/hmg\/ddv496","article-title":"The molecular basis of variable phenotypic severity among common missense mutations causing Rett syndrome","volume":"25","author":"Brown","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2022.109022_bib9","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1126\/science.1153252","article-title":"MeCP2, a key contributor to neurological disease, activates and represses transcription","volume":"320","author":"Chahrour","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2022.109022_bib10","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.tips.2017.03.008","article-title":"mGlu2\/3 receptor antagonists as novel antidepressants","volume":"38","author":"Chaki","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2022.109022_bib11","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/85906","article-title":"Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice","volume":"27","author":"Chen","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2022.109022_bib12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3389\/fnbeh.2014.00219","article-title":"Activation of mGluR2\/3 underlies the effects of N-acetylcystein on amygdala-associated autism-like phenotypes in a valproate-induced rat model of autism","volume":"8","author":"Chen","year":"2014","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109022_bib13","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.brainres.2010.11.032","article-title":"Pharmacological reversal of synaptic plasticity deficits in the mouse model of fragile X syndrome by group II mGluR antagonist or lithium treatment","volume":"1380","author":"Choi","year":"2011","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109022_bib14","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1093\/hmg\/ddh282","article-title":"Mild overexpression of MeCP2 causes a progressive neurological disorder in mice","volume":"13","author":"Collins","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2022.109022_bib15","article-title":"Safety and efficacy of genetic MECP2 supplementation in the R294X mouse model of Rett syndrome","author":"Collins","year":"2021","journal-title":"Gene Brain Behav."},{"key":"10.1016\/j.neuropharm.2022.109022_bib16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.mcn.2014.01.005","article-title":"MeCP2 is required for activity-dependent refinement of olfactory circuits","volume":"59","author":"Degano","year":"2014","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109022_bib17","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.euroneuro.2015.03.012","article-title":"Modulation of Rho GTPases rescues brain mitochondrial dysfunction, cognitive deficits and aberrant synaptic plasticity in female mice modeling Rett syndrome","volume":"25","author":"De Filippis","year":"2015","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2022.109022_bib18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.biopsych.2021.02.970","article-title":"Activating mGlu3 metabotropic glutamate receptors rescues schizophrenia-like cognitive deficits through metaplastic adaptations within the Hippocampus","volume":"90","author":"Dogra","year":"2021","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109022_bib19","doi-asserted-by":"crossref","first-page":"12604","DOI":"10.1073\/pnas.0405077101","article-title":"Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia","volume":"101","author":"Egan","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2022.109022_bib20","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1021\/acschemneuro.7b00414","article-title":"Genetic reduction or negative modulation of mGlu7 does not impact anxiety and fear learning phenotypes in a mouse model of MECP2 duplication syndrome","volume":"9","author":"Fisher","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109022_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1756-6606-7-31","article-title":"Comprehensive behavioral study of mGluR3 knockout mice: implication in schizophrenia related endophenotypes","volume":"7","author":"Fujioka","year":"2014","journal-title":"Mol. Brain"},{"key":"10.1016\/j.neuropharm.2022.109022_bib22","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/npp.2015.233","article-title":"The antidepressant effects of an mGlu2\/3 receptor antagonist and ketamine require AMPA receptor stimulation in the mPFC and subsequent activation of the 5-HT neurons in the DRN","volume":"41","author":"Fukumoto","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109022_bib23","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.neuron.2008.07.030","article-title":"Deletion of Mecp2 in Sim1-expressing neurons reveals a critical role for MeCP2 in feeding behavior, aggression, and the response to stress","volume":"59","author":"Fyffe","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109022_bib24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/mt.2012.200","article-title":"Improved survival and reduced phenotypic severity following AAV9\/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice","volume":"21","author":"Gadalla","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuropharm.2022.109022_bib25","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.omtm.2017.04.007","article-title":"Development of a novel AAV gene therapy cassette with improved safety features and efficacy in a mouse model of rett syndrome","volume":"5","author":"Gadalla","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.neuropharm.2022.109022_bib26","doi-asserted-by":"crossref","first-page":"13612","DOI":"10.1523\/JNEUROSCI.1854-13.2013","article-title":"Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome","volume":"33","author":"Garg","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109022_bib27","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.biopsych.2005.07.025","article-title":"Postnatal loss of methyl-CpG binding protein 2 in the forebrain is sufficient to mediate behavioral aspects of Rett syndrome in mice","volume":"59","author":"Gemelli","year":"2006","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109022_bib28","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2174\/18715273113129990079","article-title":"mGlu2\/3 agonist-induced hyperthermia: an in vivo assay for detection of mGlu2\/3 receptor antagonism and its relation to antidepressant-like efficacy in mice","volume":"12","author":"Gleason","year":"2013","journal-title":"CNS Neurol. Disord. - Drug Targets"},{"key":"10.1016\/j.neuropharm.2022.109022_bib29","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nn.2997","article-title":"Rett syndrome mutation MeCP2 T158A disrupts DNA binding, protein stability and ERP responses","volume":"15","author":"Goffin","year":"2011","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109022_bib30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1124\/jpet.117.246991","article-title":"Total RNA sequencing of rett syndrome autopsy samples identifies the M4 muscarinic receptor as a novel therapeutic target","volume":"365","author":"Gogliotti","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109022_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai7459","article-title":"mGlu7 potentiation rescues cognitive, social, and respiratory phenotypes in a mouse model of Rett syndrome","volume":"9","author":"Gogliotti","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuropharm.2022.109022_bib32","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/hmg\/ddw074","article-title":"mGlu5 positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome","volume":"25","author":"Gogliotti","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2022.109022_bib33","doi-asserted-by":"crossref","first-page":"35320","DOI":"10.1038\/srep35320","article-title":"The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia","volume":"6","author":"Griebel","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2022.109022_bib34","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1126\/science.1138389","article-title":"Reversal of neurological defects in a mouse model of Rett syndrome","volume":"315","author":"Guy","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2022.109022_bib35","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/85899","article-title":"A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome","volume":"27","author":"Guy","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2022.109022_bib36","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/0269881108089818","article-title":"The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia","volume":"22","author":"Harrison","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109022_bib37","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.02676","article-title":"Rett-causing mutations reveal two domains critical for MeCP2 function and for toxicity in MECP2 duplication syndrome mice","volume":"3","author":"Heckman","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.neuropharm.2022.109022_bib38","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0896-6273(00)80909-5","article-title":"Formation of temporal memory requires NMDA receptors within CA1 pyramidal neurons","volume":"25","author":"Huerta","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109022_bib39","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.pbb.2006.05.021","article-title":"Effects of the mGluR2\/3 agonist LY379268 on ketamine-evoked behaviours and neurochemical changes in the dentate gyrus of the rat","volume":"84","author":"Imre","year":"2006","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109022_bib40","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1527-3458.2007.00024.x","article-title":"The preclinical properties of a novel group II metabotropic glutamate receptor agonist LY379268","volume":"13","author":"Imre","year":"2007","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.neuropharm.2022.109022_bib41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2202-11-19","article-title":"Abnormalities of cell packing density and dendritic complexity in the MeCP2 A140V mouse model of Rett syndrome\/X-linked mental retardation","volume":"11","author":"Jentarra","year":"2010","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109022_bib42","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41386-018-0192-8","article-title":"Antidepressant potential of metabotropic glutamate receptor mGlu2 and mGlu3 negative allosteric modulators","volume":"44","author":"Joffe","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109022_bib43","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/s41380-017-0015-z","article-title":"Metabotropic glutamate receptor subtype 3 gates acute stress-induced dysregulation of amygdalo-cortical function","volume":"24","author":"Joffe","year":"2019","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109022_bib44","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.neuron.2019.09.044","article-title":"mGlu2 and mGlu3 negative allosteric modulators divergently enhance thalamocortical transmission and exert rapid antidepressant-like effects","volume":"105","author":"Joffe","year":"2020","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109022_bib45","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1016\/j.celrep.2016.08.004","article-title":"Tcf4 regulates synaptic plasticity, DNA methylation, and memory function","volume":"16","author":"Kennedy","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuropharm.2022.109022_bib46","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1093\/hmg\/ddn061","article-title":"Defective body-weight regulation, motor control and abnormal social interactions in Mecp2 hypomorphic mice","volume":"17","author":"Kerr","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2022.109022_bib47","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1101\/gad.320325.118","article-title":"Toxicity of overexpressed MeCP2 is independent of HDAC3 activity","volume":"32","author":"Koerner","year":"2018","journal-title":"Genes Dev."},{"key":"10.1016\/j.neuropharm.2022.109022_bib48","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbr.2014.03.008","article-title":"mGluR3 knockout mice show a working memory defect and an enhanced response to MK-801 in the T- and Y-maze cognitive tests","volume":"266","author":"Lainiola","year":"2014","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109022_bib49","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1172\/JCI90967","article-title":"Elevating expression of MeCP2 T158M rescues DNA binding and Rett syndrome-like phenotypes","volume":"127","author":"Lamonica","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuropharm.2022.109022_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2007.08.039","article-title":"Ube3a mRNA and protein expression are not decreased in Mecp2R168X mutant mice","volume":"1180","author":"Lawson-Yuen","year":"2007","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109022_bib51","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12864-016-2746-7","article-title":"Transcriptome analysis of human brain tissue identifies reduced expression of complement complex C1Q Genes in Rett syndrome","volume":"17","author":"Lin","year":"2016","journal-title":"BMC Genom."},{"key":"10.1016\/j.neuropharm.2022.109022_bib52","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1242\/dmm.029959","article-title":"A small-molecule TrkB ligand restores hippocampal synaptic plasticity and object location memory in Rett syndrome mice","volume":"10","author":"Li","year":"2017","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.neuropharm.2022.109022_bib53","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1172\/JCI78167","article-title":"MECP2 disorders: from the clinic to mice and back","volume":"125","author":"Lombardi","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuropharm.2022.109022_bib54","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1073\/pnas.0401626101","article-title":"Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice","volume":"101","author":"Luikenhuis","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2022.109022_bib55","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.52629","article-title":"Whole brain delivery of an instability-prone Mecp2 transgene improves behavioral and molecular pathological defects in mouse models of Rett syndrome","volume":"9","author":"Luoni","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.neuropharm.2022.109022_bib56","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1038\/npp.2011.145","article-title":"Fractionation of spatial memory in GRM2\/3 (mGlu2\/mGlu3) double knockout mice reveals a role for group II metabotropic glutamate receptors at the interface between arousal and cognition","volume":"36","author":"Lyon","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109022_bib57","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13041-017-0293-z","article-title":"Targeting metabotropic glutamate receptors for novel treatments of schizophrenia","volume":"10","author":"Maksymetz","year":"2017","journal-title":"Mol. Brain"},{"key":"10.1016\/j.neuropharm.2022.109022_bib58","doi-asserted-by":"crossref","first-page":"105235","DOI":"10.1016\/j.nbd.2020.105235","article-title":"Severe offtarget effects following intravenous delivery of AAV9-MECP2 in a female mouse model of Rett syndrome","volume":"149","author":"Matagne","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2022.109022_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2016.12.009","article-title":"A codon-optimized Mecp2 transgene corrects breathing deficits and improves survival in a mouse model of Rett syndrome","volume":"99","author":"Matagne","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2022.109022_bib60","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/(SICI)1098-1063(1998)8:6<638::AID-HIPO6>3.0.CO;2-Q","article-title":"Hippocampectomy disrupts auditory trace fear conditioning and contextual fear conditioning in the rat","volume":"8","author":"McEchron","year":"1998","journal-title":"Hippocampus"},{"key":"10.1016\/j.neuropharm.2022.109022_bib61","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddaa102","article-title":"Pharmacological readthrough of R294X Mecp2 in a novel mouse model of Rett Syndrome","author":"Merritt","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2022.109022_bib62","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/hmg\/ddi016","article-title":"Abnormalities of social interactions and home-cage behavior in a mouse model of Rett syndrome","volume":"14","author":"Moretti","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2022.109022_bib63","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1523\/JNEUROSCI.2623-05.2006","article-title":"Learning and memory and synaptic plasticity are impaired in a mouse model of Rett syndrome","volume":"26","author":"Moretti","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109022_bib64","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1038\/npp.2014.43","article-title":"GABAA receptor antagonism ameliorates behavioral and synaptic impairments associated with MeCP2 overexpression","volume":"39","author":"Na","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109022_bib65","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1523\/JNEUROSCI.6000-11.2012","article-title":"A mouse model for MeCP2 duplication syndrome: MeCP2 overexpression impairs learning and memory and synaptic transmission","volume":"32","author":"Na","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109022_bib66","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1124\/jpet.110.170506","article-title":"Effects of a positive allosteric modulator of group II metabotropic glutamate receptors, LY487379, on cognitive flexibility and impulsive-like responding in rats","volume":"335","author":"Nikiforuk","year":"2010","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109022_bib67","doi-asserted-by":"crossref","first-page":"10912","DOI":"10.1523\/JNEUROSCI.1869-07.2007","article-title":"Brain-derived neurotrophic factor expression and respiratory function improve after ampakine treatment in a mouse model of Rett syndrome","volume":"27","author":"Ogier","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109022_bib68","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13229-017-0174-4","article-title":"RNA sequencing and proteomics approaches reveal novel deficits in the cortex of Mecp2-deficient mice, a model for Rett syndrome","volume":"8","author":"Pacheco","year":"2017","journal-title":"Mol. Autism."},{"key":"10.1016\/j.neuropharm.2022.109022_bib69","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/brain\/awl022","article-title":"Mecp2 deficiency is associated with learning and cognitive deficits and altered gene activity in the hippocampal region of mice","volume":"129","author":"Pelka","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2022.109022_bib70","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1093\/hmg\/ddv030","article-title":"Rett syndrome like phenotypes in the R255X Mecp2 mutant mouse are rescued by MECP2 transgene","volume":"24","author":"Pitcher","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2022.109022_bib71","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1093\/cercor\/bhi022","article-title":"The metabotropic glutamate receptor mGluR3 is critically required for hippocampal long-term depression and modulates long-term potentiation in the dentate gyrus of freely moving rats","volume":"15","author":"P\u00f6schel","year":"2005","journal-title":"Cerebr. Cortex"},{"key":"10.1016\/j.neuropharm.2022.109022_bib72","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.S51.002","article-title":"Rett syndrome gene therapy improves survival and ameliorates behavioral phenotypes in MeCP2 null (S51.002)","author":"Powers","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2022.109022_bib73","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.21715","article-title":"Autism and other neuropsychiatric symptoms are prevalent in individuals with MeCP2 duplication syndrome","volume":"66","author":"Ramocki","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2022.109022_bib74","doi-asserted-by":"crossref","first-page":"11521","DOI":"10.1523\/JNEUROSCI.1519-16.2016","article-title":"Activation of group II metabotropic glutamate receptors promotes LTP induction at schaffer collateral-CA1 pyramidal cell synapses by priming NMDA receptors","volume":"36","author":"Rosenberg","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109022_bib75","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1111\/j.1460-9568.2007.05466.x","article-title":"Treatment with desipramine improves breathing and survival in a mouse model for Rett syndrome","volume":"25","author":"Roux","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109022_bib76","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.172","article-title":"Meta-analysis supports GWAS-implicated link between GRM3 and schizophrenia risk","volume":"7","author":"Saini","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109022_bib77","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/hmg\/ddn062","article-title":"A partial loss of function allele of methyl-CpG-binding protein 2 predicts a human neurodevelopmental syndrome","volume":"17","author":"Samaco","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2022.109022_bib78","doi-asserted-by":"crossref","first-page":"21966","DOI":"10.1073\/pnas.0912257106","article-title":"Loss of MeCP2 in aminergic neurons causes cell-autonomous defects in neurotransmitter synthesis and specific behavioral abnormalities","volume":"106","author":"Samaco","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2022.109022_bib79","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/ng.1066","article-title":"Crh and Oprm1 mediate anxiety-related behavior and social approach in a mouse model of MECP2 duplication syndrome","volume":"44","author":"Samaco","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2022.109022_bib80","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/hmg\/dds406","article-title":"Female Mecp2(+\/-) mice display robust behavioral deficits on two different genetic backgrounds providing a framework for pre-clinical studies","volume":"22","author":"Samaco","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2022.109022_bib81","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012433","article-title":"The enhancement of activity rescues the establishment of Mecp2 null neuronal phenotypes","volume":"13","author":"Scaramuzza","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.neuropharm.2022.109022_bib82","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/gbb.12070","article-title":"MeCP2 R168X male and female mutant mice exhibit Rett-like behavioral deficits","volume":"12","author":"Schaevitz","year":"2013","journal-title":"Gene Brain Behav."},{"key":"10.1016\/j.neuropharm.2022.109022_bib83","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci","volume":"511","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109022_bib84","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0896-6273(02)00768-7","article-title":"Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3","volume":"35","author":"Shahbazian","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109022_bib85","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1093\/brain\/awab182","article-title":"Engineered microRNA-based regulatory element permits safe high-dose miniMECP2 gene therapy in Rett mice","volume":"144","author":"Sinnett","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2022.109022_bib86","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.omtm.2017.04.006","article-title":"Improved MECP2 gene therapy extends the survival of MeCP2-null mice without apparent toxicity after intracisternal delivery","volume":"5","author":"Sinnett","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.neuropharm.2022.109022_bib87","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1093\/cercor\/bhx282","article-title":"Contextual fear extinction induces hippocampal metaplasticity mediated by metabotropic glutamate receptor 5","volume":"28","author":"Stansley","year":"2018","journal-title":"Cerebr. Cortex"},{"key":"10.1016\/j.neuropharm.2022.109022_bib88","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.neuroscience.2007.02.009","article-title":"Behavioral and anatomical abnormalities in Mecp2 mutant mice: a model for Rett syndrome","volume":"146","author":"Stearns","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2022.109022_bib89","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrd1630","article-title":"Metabotropic glutamate receptors as novel targets for anxiety and stress disorders","volume":"4","author":"Swanson","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2022.109022_bib90","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature16159","article-title":"Reversal of phenotypes in MECP2 duplication mice using genetic rescue or antisense oligonucleotides","volume":"528","author":"Sztainberg","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109022_bib91","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1523\/JNEUROSCI.1305-17.2017","article-title":"Common pathophysiology in multiple mouse models of pitt-hopkins syndrome","volume":"38","author":"Thaxton","year":"2018","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109022_bib92","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nature24058","article-title":"Radically truncated MeCP2 rescues Rett syndrome-like neurological defects","volume":"550","author":"Tillotson","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109022_bib93","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1086\/444549","article-title":"Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males","volume":"77","author":"Van Esch","year":"2005","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.neuropharm.2022.109022_bib94","article-title":"Profiling beneficial and potential adverse effects of MeCP2 overexpression in a hypomorphic Rett syndrome mouse model","author":"Vermudez","year":"2021","journal-title":"Gene Brain Behav."},{"key":"10.1016\/j.neuropharm.2022.109022_bib95","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.coph.2014.11.003","article-title":"Group I and group II metabotropic glutamate receptor allosteric modulators as novel potential antipsychotics","volume":"20","author":"Walker","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109022_bib96","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1038\/npp.2017.136","article-title":"Co-activation of metabotropic glutamate receptor 3 and beta-adrenergic receptors modulates cyclic-AMP and long-term potentiation, and disrupts memory reconsolidation","volume":"42","author":"Walker","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109022_bib97","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1073\/pnas.1416196112","article-title":"Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction","volume":"112","author":"Walker","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2022.109022_bib98","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.neuroscience.2011.01.061","article-title":"Synaptic plasticity deficits in an experimental model of rett syndrome: long-term potentiation saturation and its pharmacological reversal","volume":"180","author":"Weng","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2022.109022_bib99","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00213-007-0974-x","article-title":"The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2\/3 agonist, LY379268, in mouse models predictive of antipsychotic activity","volume":"196","author":"Woolley","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109022_bib100","doi-asserted-by":"crossref","first-page":"16762","DOI":"10.1523\/JNEUROSCI.2869-13.2014","article-title":"Hippocampal metaplasticity is required for the formation of temporal associative memories","volume":"34","author":"Xu","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109022_bib101","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.resp.2007.08.009","article-title":"Oral treatment with desipramine improves breathing and life span in Rett syndrome mouse model","volume":"160","author":"Zanella","year":"2008","journal-title":"Respir. Physiol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2022.109022_bib102","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1038\/s41598-017-06916-3","article-title":"Altered visual cortical processing in a mouse model of MECP2 duplication syndrome","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2022.109022_bib103","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.1523\/JNEUROSCI.1520-05.2005","article-title":"Deficits in trace fear memory and long-term potentiation in a mouse model for fragile X syndrome","volume":"25","author":"Zhao","year":"2005","journal-title":"J. Neurosci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822000818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822000818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:37:59Z","timestamp":1777426679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390822000818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":103,"alternative-id":["S0028390822000818"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109022","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploration of group II metabotropic glutamate receptor modulation in mouse models of Rett syndrome and MECP2 Duplication syndrome","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109022"}}